Haemophilia A
83
8
8
66
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
18 trials with published results (22%)
Research Maturity
66 completed trials (80% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.6%
3 terminated out of 83 trials
95.7%
+9.1% vs benchmark
28%
23 trials in Phase 3/4
27%
18 of 66 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 66 completed trials
Clinical Trials (83)
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany
Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI
A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge
Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct